Veracyte, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +16.9%
EBITDA: +115.6%
EBIT: +184.6%
EPS: +157.6%
Free cash flow: +97.3%
Operating cash flow: +85.8%

Forward estimates

Revenue: +13.1%
EBITDA: +130.8%
EPS: +55.4%

Three-year CAGR

Revenue: +20.4%
EBITDA: +82.1%
EBIT: +359.4%
Net income: +174.9%
EPS: +162.5%
Free cash flow: +92.3%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.